首页期刊导航|中华微生物学和免疫学杂志
期刊信息/Journal information
中华微生物学和免疫学杂志
北京生物制品研究所
中华微生物学和免疫学杂志

北京生物制品研究所

沈心亮

月刊

0254-5101

cjmia@163.com

010-52245168

100024

北京市朝阳区三间房南里4号

中华微生物学和免疫学杂志/Journal Chinese Journal of Microbiology and ImmunologyCSCD北大核心CSTPCD
查看更多>>中华医学会主办。本刊以医学微生物学和免疫学的基础和应用研究及其新理论、新技术以及国内外研究进展为报道内容。设有细菌学、病毒学、分子微生物学、临床微生物学、感染免疫、疫苗学、基础免疫学、临床免疫学、分子免疫学、免疫遗传、肿瘤免疫、中药免疫、免疫治疗、免疫学技术、检测技术、述评、综述、学术会议评述、人物述林、医药信息、新书介绍等栏目。读者为本专业科研人员、教师和高、中级卫生防疫、检验工作者及大学以上学生。本刊是中国生物科学和基础医学两学科核心期刊;被CA、BA、EM、Medline等国内外多种著名检索系统收录。杂志曾获国家优秀科技期刊奖并多次获省部级优秀科技期刊奖。2001年进入国家新闻出版署建设的“中国期刊方阵”。2008年获得中国科学技术信息研究所“中国精品科技期刊”称号。
正式出版
收录年代

    2022—2023年承德市呼吸道合胞病毒的暴发流行及其临床特征研究

    马倩格高姝畅郭心悦严梦瑶...
    155-161页
    查看更多>>摘要:目的 确定呼吸道合胞病毒(respiratory syncytial virus, RSV)在承德市的流行情况及临床特征。 方法 收集2022年8月—2023年6月因呼吸道感染在承德市中心医院儿科住院治疗的患儿咽拭子478份及其临床信息,实时定量PCR检测A亚型和B亚型RSV的分子流行情况,对RSV感染患者的临床特征进行分析。 结果 67.57%(323/478)的住院患儿为RSV阳性,RSV呈暴发流行且均为RSV-A型,2022年11—12月和2023年5—6月为RSV-A型的2次感染高峰。RSV-A型阳性患儿中,86.07%(278/323)为合并其他病原体检出病例,其中与细菌共检出的例数最多,以肺炎链球菌为主,肺炎克雷伯菌次之。流感病毒A型是最常见的共检出病毒。与RSV-A型共检出患儿组相比,RSV-A型单独检出组的乳酸脱氢酶(Z=2.396,P=0.017)较高,且高于正常高值;RSV-A型共检出组的白细胞计数(Z=2.417,P=0.016)、中性粒细胞比例(Z=3.218,P=0.001)、C-反应蛋白(Z=1.998,P=0.046)和肌酐(Z=2.107,P=0.035)较高,淋巴细胞比例(Z=3.205,P=0.001)较低,但位于正常值范围。RSV-A型合并检出细菌或其他病毒的患儿临床特征无差异(P均>0.05)。 结论 RSV-A型是承德市2022—2023年呼吸道感染患儿的主要病原体,且多与细菌共检出。RSV-A型检测阳性患儿的临床特征与RSV-A型是否合并其他呼吸道病原体情况相关。 Objective To analyze the prevalence and clinical features of respiratory syncytial virus (RSV) in Chengde city. Methods From August 2022 to June 2023, throat swabs and clinical data of 478 hospitalized children with respiratory tract infection in the Chengde Central Hospital were collected. Real-time quantitative PCR was used to detect the molecular epidemiology of RSV-A and RSV-B subtypes and analyze the clinical features of patients with RSV infection. Results Among the hospitalized children, 67.57% (323/478) tested positive for RSV. The outbreak of RSV infection was caused by RSV-A subtype. The peaks of RSV-A infection occurred from November to December, 2022 and May to June, 2023. There were 86.07% (278/323) of the RSV-A-positive cases had mixed infection with other pathogens, primarily bacterial pathogens with Streptococcus pneumoniae being the most common, followed by Klebsiella pneumoniae. Influenza virus A was the most common viral pathogens causing mixed infection. The level of lactate dehydrogenase was higher in the patients with single RSV-A infection than in those with mixed infection (Z=2.396, P=0.017), and higher than the normal upper limit. Compared with the single infection group, the mixed infection group had higher white blood cell count (Z=2.417, P=0.016), neutrophil ratio (Z=3.218, P=0.001), C-reactive protein level (Z=1.998, P=0.046) and creatinine level (Z=2.107, P=0.035), and lower lymphocyte ratio (Z=3.205, P=0.001), but they were all within the normal range. There were no significant differences in the clinical features between RSV-A-positive patients co-infected with bacteria or other viruses (all P>0.05). Conclusions RSV-A is the leading cause of respiratory tract infection in children in Chengde from 2022 to 2023, and often co-detected with bacteria. The mixed infection with other respiratory pathogens is related to the clinical features of patients with RSV-A infection.

    呼吸道合胞病毒流行特征临床特征儿童

    基于N-ELISA的呼吸道合胞病毒快速中和抗体检测方法的建立

    孙誉芳赵慧杨惠洁谢莹...
    162-169页
    查看更多>>摘要:目的 制备针对呼吸道合胞病毒(RSV) N蛋白的兔多克隆抗体,以其作为检测抗体建立基于ELISA的快速中和抗体检测方法。 方法 构建pET30a-N质粒,表达纯化N蛋白,免疫新西兰兔制备针对RSV N蛋白的多克隆抗体作为检测抗体。阳性血清系列稀释后与100半数组织培养感染剂量(TCID50)/孔的RSV中和,接种Hep-2细胞培养,80%丙酮固定细胞,ELISA方法检测感染细胞中病毒的N蛋白,当每孔的吸光度值低于临界值时,视为中和试验阳性孔,阳性孔血清的最高稀释度为该血清的中和抗体滴度。优化抗体稀释度、检测时间、细胞密度及中和时间,建立基于N-ELISA的中和抗体检测方法,对建立的实验方法进行细胞代次、边缘孔效应、准确性、重复性以及精密度验证,初步应用于人RSV IgG阳性血清检测,分析与微量中和法的相关性。 结果 成功构建出pET30a-N质粒,表达纯化的N蛋白纯度较高,特异性良好;三免后兔血清效价为1∶51 200,可特异性结合RSV;制备的抗RSV N兔多抗的效价为1∶51 200,特异性良好,建立的快速中和抗体检测方法在4 d就可检测,中和时间可缩短至30 min,细胞代次、96孔板位置(边缘孔和非边缘孔)对该方法检测无影响,重复性、精密性、准确度良好,建立的方法和微量中和法检测64份RSV IgG阳性人血清,相关系数为0.929 6,证明两种方法具有良好的正相关性。 结论 成功建立基于ELISA的快速中和抗体检测方法,可用于评价RSV疫苗接种后的血清抗体水平。 Objective To prepare rabbit polyclonal antibodies against respiratory syncytial virus (RSV) N protein and use them as the detection antibodies to establish a N-ELISA-based method for rapid detection of neutralizing antibodies. Methods A plasmid of pET30a-N for the expression of RSV N protein was constructed. After purification, the protein was immunized into New Zealand rabbits to prepare polyclonal antibodies, which were used as the detection antibodies. Positive serum samples were diluted and used to neutralize RSV (100 TCID50/well). Hep-2 cells were inoculated and cultured, and then the cells were fixed with 80% acetone. ELISA was performed to detect RSV N protein in infected cells. When the absorbance value of a well was below the cut-off value, it was regarded as the positive well in the neutralization test. The highest dilution of a positive well serum was the neutralizing antibody titer. After optimizting the antibody dilution, detection time, cell density and the duration of neutralization, the method for neutralizing antibody detection was established based on N-ELISA. The established method was verified by analyzing the influences of different cell generations and edge effects, and calculating the accuracy, repeatability and precision. The correlation between the established method and microneutralization method was analyzed by detecting human RSV IgG-positive serum. Results The plasmid pET30a-N was successfully constructed, and the expressed N protein showed high purity and good specificity. After the third immunization, the antibody titer in rabbit serum was 1∶51 200, and the antibodies could specifically bind to RSV. The prepared rabbit anti-RSV N polyclonal antibodies had a titer of 1∶51 200, and showed good specificity. The neutralizing antibodies could be detected on day 4 with the established method, and the duration of neutralization was shortened to 30 min. Cell generations and the position of wells in the 96-well plate (edge well and non-edge well) had no significant effect on the method, and the repeatability, precision and accuracy of the method were good. In the detection of 64 RSV IgG-positive human serum samples by the established method and microneutralization method, the correlation coefficient was 0.929 6, indicating a good positive correlation between the two methods. Conclusions A N-ELISA-based method for rapid neutralizing antibody detection is successfully established, which can be used to evaluate the serum antibody level after RSV vaccination.

    呼吸道合胞病毒中和抗体酶联免疫吸附试验

    基于网络药理学和动物体内试验验证云实感冒合剂对呼吸道合胞病毒作用

    徐庆胜李玉迁蒋立娜魏洪...
    170-182页
    查看更多>>摘要:目的 基于网络药理学和体内试验探讨云实感冒合剂抗呼吸道合胞病毒(respiratory syncytial virus,RSV)的作用机制。 方法 网络药理学预测:运用TCMSP、GeneCards等数据库预测云实感冒合剂干预RSV的活性成分及作用靶点。利用Cytoscape 3.2.1软件构建中药成分-疾病靶点网络图。通过STRING数据库分析蛋白质相互作用关系。借助Metascape数据库进行富集分析。采用分子对接技术分析验证网络药理学结果。云实感冒合剂干预RSV感染验证试验:滴鼻法建立RSV小鼠模型,灌胃合剂后检测血常规、肺指数,观察肺组织病理变化,流式细胞术检测外周血T细胞亚群,ELISA检测血清TNF-α、IL-6、IL-1β含量,RT-PCR检测肺组织中TLR4、NF-κB和RSV-N基因mRNA相对水平。 结果 分析获得云实感冒合剂有效活性成分41个,抗RSV靶点111个,富集得到167条信号通路,主要是PI3K/AKT、MAPK、Toll-like等信号通路。分子对接结果显示,云实感冒合剂活性成分木犀草素、山奈酚、槲皮素与RSV-G、RSV-F、PI3K、AKT1、Bcl-2结合能均小于0 kcal/mol。体内试验结果显示,与RSV组相比,云实感冒合剂高剂量组白细胞、淋巴细胞计数升高、肺指数降低,差异有统计学意义(P<0.05)。HE染色显示RSV组肺组织增生,肺泡壁变厚,间质内有炎性细胞浸润,利巴韦林组和云实感冒合剂低、中、高剂量组中肺泡大小趋向均匀,肺泡壁厚度均一。与RSV组相比,云实感冒合剂低、中、高剂量组的CD3+、CD4+、CD8+ T淋巴细胞数量明显升高,CD4+/CD8+T细胞数量比值降低,血清中TNF-α、IL-6、IL-1β含量下降,肺组织中病毒载量和TLR4、NF-κB mRNA水平降低,差异均具有统计学意义(P<0.05)。 结论 云实感冒合剂通过多成分、多靶点、多通路发挥调控RSV感染,主要通过缓解肺组织病理损伤,减轻炎症反应,其机制可能与抑制TLR4/NF-κB通路激活有关。 Objective To investigate the mechanism of Yunshi Ganmao Heji against respiratory syncytial virus (RSV) infection based on network pharmacology and in vivo experiments. Methods Network pharmacological prediction: Several databases including TCMSP and GeneCards were used to predict the active ingredients and targets of Yunshi Ganmao Heji in the intervention of RSV infection. Cytoscape 3.2.1 software was used to construct the traditional Chinese medicine component-disease target network diagram. The interactions between proteins were analyzed by STRING database. GO functional enrichment analysis and KEGG pathway enrichment analysis were performed using Metascape database. Molecular docking technology was used to verify the results of network pharmacology. Experimental verification of Yunshi Ganmao Heji for the intervention of RSV infection: A mouse model of RSV infection was established through intranasal infection. After the administration of Yunshi Ganmao Heji, blood routine test results, lung indexes and pathological changes in lung tissue were analyzed. Peripheral blood T cell subsets were detected by flow cytometry. The levels of TNF-α, IL-6 and IL-1β in serum were detected by ELISA. RT-PCR was used to detect the relative expression of TLR4, NF-κB and RSV-N gene at mRNA level in lung tissues. Results A total of 41 active ingredients of Yunshi Ganmao Heji and 111 drug targets for RSV infection were obtained. Besides, 167 signaling pathways mainly including PI3K/AKT, MAPK and Toll-like receptor signaling pathways were obtained. Molecular docking results showed that the binding energies of luteotin, kaempferol and quercetin, three active ingredients of Yunshi Ganmao Heji, with RSV-G, RSV-F, PI3K, AKT1 and Bcl-2 were less than 0 kcal/mol. In vivo experiment results showed that compared with RSV group, the counts of white blood cells and lymphocytes increased and the lung index decreased in high-dose Yunshi Ganmao Heji group, with statistically significant difference (P<0.05). HE staining showed pulmonary hyperplasia, thickened alveolar wall and inflammatory cell infiltration in interstitium in RSV group. Alveoli in ribavirin group as well as low-dose, medium-dose and high-dose Yunshi Ganmao Heji groups tended to be of uniform size, and the alveolar walls was roughly uniform in thickness. Compared with RSV group, the low-dose, medium-dose and high-dose Yunshi Ganmao Heji groups showed significantly increased numbers of CD3+, CD4+ and CD8+ T lymphocytes, decreased CD4+ /CD8+ T cell ratio, lower levels of TNF-α, IL-6, IL-1β in serum, and reduced viral load and inhibited expression of TLR4 and NF-κB at mRNA level in lung tissues (P<0.05). Conclusions Yunshi Ganmao Heji can regulate RSV infection by targeting multiple targets and pathways with several active ingredients. Its main functions are to alleviate pathological injury in lung tissues and reduce inflammatory response, and the possible mechanism underlying the antiviral functions may be related to its inhibitory effect on the activation of TLR4/NF-κB pathway.

    云实感冒合剂网络药理学呼吸道合胞病毒体内试验分子对接

    呼吸道合胞病毒受体研究进展

    李淑艳杨惠洁权娅茹李长贵...
    183-188页
    查看更多>>摘要:呼吸道合胞病毒(respiratory syncytial virus, RSV)是急性呼吸道感染的主要病原体之一,给全世界造成了巨大的负担。病毒与宿主细胞受体识别和相互作用,是建立感染的关键初始步骤,受体分布影响病毒的细胞嗜性和组织嗜性,影响病毒在宿主体内的复制和增殖。但目前RSV受体尚不明确,这也是阻碍RSV疫苗及治疗性药物研发的原因之一。本文通过对现有的RSV受体进行综述,以期对RSV疫苗及治疗性药物的研发提供思路。 Respiratory syncytial virus (RSV) is one of the major pathogens of acute respiratory infections, becoming a huge global burden. Virus-receptor interactions play a key role in the pathogenesis of RSV infection. The distribution of receptors influences the cellular and the tissue tropism of RSV as well as the viral replication and proliferation in the host. However, the RSV receptors are currently unknown, which is one of the reasons that hinders the development of RSV vaccines and therapeutic drugs. In this study, the existing RSV receptors are reviewed with the hope to provide ideas for the research of RSV vaccines and therapeutic drugs.

    呼吸道合胞病毒受体疫苗